Abstract
The use of nanoparticles in medicine will require sensors that can serve as guidance molecules for targeting the particles to appropriate sites in the body. Another set of sensors will be needed to allow the particles to respond to features at the target, such as inflammation, cell death, etc. Compounds that target the vascular endothelium provide one answer to the guidance and sensing problems. The endothelium of blood vessels is readily accessible from the blood stream, and the vessels in different tissues carry unique molecular signatures. Pathological lesions also put their signature on the vasculature; in tumors, both blood and lymphatic vessels differ from normal vessels. Peptides and antibodies that recognize vascular signatures have been shown to be useful in directing therapeutic agents to targets such as tumors. The targeting can enhance the efficacy of the therapy while reducing side effects. Combining the targeting technology with nanoparticles can take us a step closer to truly smart nanodevices.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
K. Alitalo and P. Carmeliet. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 1:219–227, 2002.
M.E. Akerman, W.C. Chan, P. Laakkonen, S.N. Bhatia, and E. Ruoslahti. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. U.S.A., 99:12617–12621, 2002.
W. Arap, W. Haedicke, M. Bernasconi,, R. Kain, D. Rajotte, S. Krajewski, H.M. Ellerby, D.E. Bredesen, R. Pasqualini, and E. Ruoslahti. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. U.S.A., 99:1527–1531, 2002.
W. Arap, R. Pasqualini, and E. Ruoslahti. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279:377–380, 1998.
P.J. Bates, J.B. Kahlon, S.D. Thomas, Trent, and D.M. Millet. Antiproliferative activity of G-rich Oligonucleotides correlates with protein binding. J.Biol.Chem., 274:26369–26377, 1999.
D.M. Brown, M. Pellecchia, and E. Ruoslahti. Drug identification through in vivo screening of chemical libraries. ChemBioChemistry, 5:871–875.
D. Brown, and E. Ruoslahti. Metadherin, a novel cell-surface protein in breast tumors that mediates lung metastasis. Cancer Cell, 5:365–374, 2004.
S. Christian, J. Pilch, K. Porkka, P. Laakkonen, and E. Ruoslahti. Nucleoilin expressed at the cell surface is a marker of endothelial cells in tumor blood vessels. J. Cell. Biol., 163:871–878, 2003.
F. Curnis, A. Sacchi, L. Borgna, F. Magni, A. Gasparri, and A. Corti. Enhancement of tumor necrosis factor antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nature Biotech., 18:1185–1190, 2000.
F. Curnis, G. Arrigoni, A. Sacchi, L. Fischetti, W. Arap, R. Pasqualini, and A. Corti. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res., 62:867–874, 2002.
A.M. Derfus, W.C. Chan, and S.N. Bhatia. Probing the cytotoxicity of semiconductor quantum dots. Nano Letters, 4:11–18, 2004.
A.M. Derfus, W.C Chan, and S.N. Bhatia, Intracellular delivery of quantum dots for live cell labeling and organelle tracking. Adv. Mat. published online 5/19/04, 2004.
B.S. Ding, Y.J. Zhou, X. Y. Chen, J. Zhang, P.X. Zhang, Z. Y. Sun, X. Y. Tan, and J. N. Liu. Lung endothelium targeting for pulmonary embolism thrombolysis. Circulation, 108:2892–2898, 2003.
Ellerby, W. Arap, L.M. Ellerby, R. Kain, R. Andrusiak, G. D. Rio, S. Krajewski, C. R. Lombardo, R., Rao, E. Ruoslahti. et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med., 5:1032–1038, 1999.
B.P. Eliceiri and D.A. Cheresh. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest., 103:1227–1230, 1999.
B.P. Eliceiri and D.A. Cheresh. Adhesion events in angiogenesis. Curr. Opini. Cell Biol., 13:563–568, 2001.
M. Essler and E. Ruoslahti. Molecular specialization of breast vasculature: a breast-homing phagedisplayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U.S.A., 99:2252–2257, 2002.
M.N. Fukuda, C. Ohyama, K. Lowitz, O. Matsuo, R. Pasqualini, E., Ruoslahti, and M. Fukuda. Apeptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res., 60:450–456, 2000.
D.M. Gerlag, E. Borges, P.P. Tak, H.M. Ellerby, D.E., Bredesen, R. Pasqualini, E. Ruoslahti, and G.S. Firestein. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arth. Res., 3:357–361, 2001.
C. Halin, S. Rondini, F. Nilsson, A. Berndt, H. Kosmehl, L. Zardi, and D. Neri. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol., 20:264–269, 2002.
Y.S. Haviv, J.L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res., 62:4273–4281, 2002.
J.A. Hoffman, E. Giraudo M. Singh, M. Inoue, K. Porkka, D. Hanahan, and E. Ruoslahti. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell, 4:383–391, 2003.
J. D. Hood, M. Bednarski, R. Frausto, S. Guccione, R. A. Reisfeld, R. Xiang, and D. A. Cheresh. Tumor regression by targeted gene delivery to the neovasculature. Science, 296:2404–2407, 2002.
P. Houston, J. Goodman, A. Lewis, C. J. Campbell, and M. Braddock. Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging. FEBS Lett., 492:73–77, 2001.
R.C. Johnson, D. Zhu, H.G. Augustin-Voss, and B.U. Pauli. Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung metastatic rat breast and prostate carcinoma cells. J. Cell Biol., 121:1423–1432, 1993.
J.A. Joyce, P. Laakkonen, M. Bernasconi, G. Bergers, E. Ruoslahti, and D. Hanahan. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 4:393–403, 2003.
S. Kim, K. Bell, S.A. Mousa, and J.A. Varner. A regulation of angiogenesis in vivo by ligation of integrin α5Β1 with the central cell-binding domain of fibronectin. Am. J. Pathol., 156:1345–1362, 2000.
P. Laakkonen, K. Porkka, J.A. Hoffman, and E. Ruoslahti. A tumor-homing peptide with a lymphatic vesselrelated targeting specificity. Nat. Med., 8:743–751, 2002.
P. Laakkonen, M.E. Akerman, H. Biliran, M. Yang, F. Ferrer, T. Karpanen, R.M. Hoffman, and E. Ruoslathi. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. U.S.A., 2004.
ü. Langel. Cell-Penetrating Peptides: Processes and Applications. Boca Raton, Florida, CRC Press, 2003.
G.M. Lanza and S.A. Wickline. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr. Prob. Cardiol., 28:625–653, 2003.
D.P. McIntosh, X.Y. Tan, P. Oh, and J. E. Schnitzer. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. U.S.A., 99:1996–2001, 2002.
R. Pasqualini and E. Ruoslahti. Organ targeting in vivo using phage display peptide libraries. Nature, 380:364–366, 1996.
R. Pasqualini, E. Koivunen, R. Kain, J. Lahdenranta, M. Sakamoto, A. Stryhn, R. A. Ashmun, L. H. Shapiro, W. Arap, and E. Ruoslahti. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60:722–727, 2000.
K. Porkka, P. Laakkonen, J.A. Hoffman, M. Bernasconi, and E. Ruoslahti. Targeting of peptides to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. U.S.A., 99:7444–7449, 2002.
D. Rajotte and E. Ruoslahti. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J. Biol. Chem., 274:11593–11598, 1999.
E. Ruoslahti. Specialization of tumour vasculature. Nat. Rev. Cancer, 2:83–90, 2002.
E. Ruoslahti, RGD story: A personal account. A landmark essay. Matrix Biol., 22:459–465, 2003.
E. Ruoslahti and D. Rajotte. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol., 18:813–827, 2000.
T.J. Wickham. Targeting adenovirus. Gene Ther., 7:110–114, 2000.
P.M. Winter, S.D. Caruthers, A. Kassner, T.D. Harris, L.K. Chinen, J.S. Allen, E.K. Lacy, H. Zhang, J.D. Robertson, S.A. Wickline, and G.M. Lanza. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res., 63:5838–5843, 2003.
L. Zhang, J.A. Hoffman, and E. Ruoslahti. Molecular profiling of heart endothelial cell. Circulation, (In press) 2005.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Ruoslahti, E. (2006). Vascular Zip Codes and Nanoparticle Targeting. In: Ferrari, M., Desai, T., Bhatia, S. (eds) BioMEMS and Biomedical Nanotechnology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-25844-7_7
Download citation
DOI: https://doi.org/10.1007/978-0-387-25844-7_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25565-1
Online ISBN: 978-0-387-25844-7
eBook Packages: EngineeringEngineering (R0)